Recent Insights » Scientific & Regulatory Review » AIMS 4.1 Promo

× Share this Video

Facebook
Twitter
Email
LinkedIn

AIMS 4.1 Promo

Share this Video
Facebook
Twitter
Email
LinkedIn

Previous Video

Stump the Safety Experts Q&A

Our experts teamed-up to take on your safety questions and provide you with tactics and strategies to overc...

Next Flipbook

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators

From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-relate...

New Blog: "Ask the IRB Experts"

Visit Blog

Other content in this Stream

Partnering with WCG Saved Small Biotech Over $12K Each Month

Read Flipbook

WCG’s PV Services Smooths Path to Approval for Emerging Biopharma

Read Flipbook

A Successful DMC Requires a Productive, Early Organizational Meeting

Read Post

59:53

Tips For A Successful Organizational DMC Meeting

Watch Video

Q&A: A Fresh Perspective from the FDA on the Final IND Safety Reporting Rule

Read Flipbook

56:30

A Fresh Perspective from the FDA on the Final IND Safety Reporting Rule

Watch Video

Don't Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise

Read Flipbook

WCG Supports Small Oncology Biotech Through Rapid Growth, Saving Hundreds of Thousands of Dollars

Read Flipbook

How WCG Statistics Collaborative Helped Breakthrough Therapy Obtain Regulatory Approval

Read Flipbook

Relieving the Safety Reporting Burden on Sites: 4 Takeaways

Read Flipbook

See How WCG Helped a Mid-tier Biopharma Respond to an Urgent FDA Request, and Adjudicate 400 Endpoints in Just a Few Short Weeks

Read Flipbook

1:00:16

The Burden of Safety Reporting on Sites: An Oncology Site’s Perspective

Watch Video

Case Study - WCG Trifecta Partners with Major Japanese Pharmaceutical Sponsor to Unify Management of Safety Records & Increase Compliance

WCG’s SafetyVigilance® Online Safety Event Solution Delivers Quality and Efficiency to Unify Enterprise Trial Management and Meet Regional Guidelines and Regulations

Read Flipbook

1:56

90 Second Insights: Safety Reporting in the Time of COVID-19

Watch Video

New Normal or Not, Safety Reporting Matters

Read Post

People, Process and Technology: The Right Combination for Successful Expert Committees

Read Post

An Estimate of the Benefit-Cost Impact of the FDA Guidance on Data Monitoring Committees

Read Flipbook

Case Study - How A Top-Pharma Client Transformed Its Safety-Reporting Process, Saving $11.2 Million in One Year

Read Flipbook

53:35

Stump the Safety Experts Q&A

Our experts teamed-up to take on your safety questions and provide you with tactics and strategies to overcome the biggest challenges plaguing your studies today.

Watch Video

Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators

From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.

Read Flipbook

Return to Home